CL2017000293A1 - Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) - Google Patents

Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)

Info

Publication number
CL2017000293A1
CL2017000293A1 CL2017000293A CL2017000293A CL2017000293A1 CL 2017000293 A1 CL2017000293 A1 CL 2017000293A1 CL 2017000293 A CL2017000293 A CL 2017000293A CL 2017000293 A CL2017000293 A CL 2017000293A CL 2017000293 A1 CL2017000293 A1 CL 2017000293A1
Authority
CL
Chile
Prior art keywords
divisional
hepatitis
compounds derived
treatment
pharmaceutical composition
Prior art date
Application number
CL2017000293A
Other languages
English (en)
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2017000293A1 publication Critical patent/CL2017000293A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>COMPUESTOS DERIVADOS DE BENZOFURANO; Y PROCESO PARA PREPARAR COMPUESTOS DERIVADOS DE BENZOFURANO (DIVISIONAL SOL. N° 393-2014)</p>
CL2017000293A 2011-08-19 2017-02-03 Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) CL2017000293A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
CL2017000293A1 true CL2017000293A1 (es) 2017-10-06

Family

ID=47746761

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014000393A CL2014000393A1 (es) 2011-08-19 2014-02-17 Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CL2017000293A CL2017000293A1 (es) 2011-08-19 2017-02-03 Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014000393A CL2014000393A1 (es) 2011-08-19 2014-02-17 Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.

Country Status (38)

Country Link
US (2) US8927593B2 (es)
EP (2) EP3199531A1 (es)
JP (2) JP6367712B2 (es)
KR (1) KR101913800B1 (es)
CN (1) CN103732065B (es)
AR (1) AR087563A1 (es)
AU (1) AU2012299295B2 (es)
BR (1) BR112014002845A2 (es)
CA (1) CA2844086A1 (es)
CL (2) CL2014000393A1 (es)
CO (1) CO6862153A2 (es)
CR (1) CR20140078A (es)
CY (1) CY1118399T1 (es)
DK (1) DK2744332T3 (es)
DO (1) DOP2014000034A (es)
EA (1) EA032841B1 (es)
ES (1) ES2611731T3 (es)
HR (1) HRP20161743T1 (es)
HU (1) HUE030300T2 (es)
IL (1) IL230487B (es)
IN (1) IN2014CN00572A (es)
JO (1) JO3281B1 (es)
LT (1) LT2744332T (es)
MA (1) MA35443B1 (es)
ME (1) ME02588B (es)
MX (1) MX354676B (es)
PE (1) PE20141201A1 (es)
PH (1) PH12014500385A1 (es)
PL (1) PL2744332T3 (es)
PT (1) PT2744332T (es)
RS (1) RS55462B1 (es)
SG (1) SG10201606883QA (es)
SI (1) SI2744332T1 (es)
SM (2) SMT201700028T1 (es)
TW (1) TWI538915B (es)
UY (1) UY34274A (es)
WO (1) WO2013028371A1 (es)
ZA (1) ZA201401020B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014001833A (es) * 2011-08-17 2014-02-27 Glaxosmithkline Llc Metodos terapeuticos.
PH12014500385A1 (en) 2011-08-19 2020-06-22 Glaxo Group Ltd Benzofuran compounds for the treatment of hepatitis c virus infections
SG11201703645XA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Long acting pharmaceutical compositions for hepatitis c
KR20170081257A (ko) * 2014-11-10 2017-07-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 C형 간염에 대한 조합 장기 작용 조성물 및 방법
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
CA3055194A1 (en) * 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
CA3088347A1 (en) * 2018-01-17 2019-07-25 Glaxosmithkline Intellectual Property Development Limited Pi4kiii.beta. inhibitors
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统
MX2023007150A (es) * 2020-12-18 2023-09-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
ES2571219T3 (es) 2001-01-25 2024-09-23 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulación de compuestos de ácido borónico
EA009943B1 (ru) * 2002-11-01 2008-04-28 Вирофарма Инкорпорейтед Соединения бензофурана, композиции и способы лечения и профилактики инфекций, вызванных вирусом гепатита с, и связанных с ним заболеваний
AU2006349612A1 (en) 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with Hepatitis C virus
PT1988779E (pt) 2006-02-16 2015-09-04 Anacor Pharmaceuticals Inc Moléculas pequenas contendo boro como agentes antiinflamatórios
EP2015757A4 (en) * 2006-05-02 2011-01-26 Anacor Pharmaceuticals Inc HYDROLYSERESISTENT, BOROYED THERAPEUTIC USES
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
ATE539070T1 (de) * 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011103063A1 (en) * 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
AU2011329485A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
MX2014001833A (es) * 2011-08-17 2014-02-27 Glaxosmithkline Llc Metodos terapeuticos.
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
PH12014500385A1 (en) 2011-08-19 2020-06-22 Glaxo Group Ltd Benzofuran compounds for the treatment of hepatitis c virus infections

Also Published As

Publication number Publication date
EA201490213A1 (ru) 2014-07-30
PL2744332T3 (pl) 2017-03-31
WO2013028371A1 (en) 2013-02-28
KR20140054287A (ko) 2014-05-08
UY34274A (es) 2013-04-05
CN103732065B (zh) 2016-10-26
AR087563A1 (es) 2014-04-03
RS55462B1 (sr) 2017-04-28
BR112014002845A2 (pt) 2017-02-21
SMT201700028T1 (it) 2017-03-08
MX2014001989A (es) 2014-02-27
ME02588B (me) 2017-06-20
ES2611731T3 (es) 2017-05-10
TWI538915B (zh) 2016-06-21
SMT201700028B (it) 2017-03-08
PH12014500385A1 (en) 2020-06-22
KR101913800B1 (ko) 2018-11-01
JP2014527529A (ja) 2014-10-16
JP6367712B2 (ja) 2018-08-01
MA35443B1 (fr) 2014-09-01
US20150080343A1 (en) 2015-03-19
DK2744332T3 (en) 2017-01-16
CL2014000393A1 (es) 2014-08-01
PT2744332T (pt) 2017-01-24
HRP20161743T1 (hr) 2017-02-24
DOP2014000034A (es) 2014-06-01
JO3281B1 (ar) 2018-09-16
SI2744332T1 (sl) 2017-01-31
EP3199531A1 (en) 2017-08-02
EA032841B1 (ru) 2019-07-31
AU2012299295B2 (en) 2016-03-31
TW201321390A (zh) 2013-06-01
US20130237501A1 (en) 2013-09-12
US9682999B2 (en) 2017-06-20
ZA201401020B (en) 2020-11-25
IL230487A0 (en) 2014-03-31
PE20141201A1 (es) 2014-10-03
EP2744332B1 (en) 2016-10-26
US8927593B2 (en) 2015-01-06
CN103732065A (zh) 2014-04-16
CA2844086A1 (en) 2013-02-28
EP2744332A1 (en) 2014-06-25
JP2017125010A (ja) 2017-07-20
CY1118399T1 (el) 2017-06-28
CR20140078A (es) 2014-03-20
LT2744332T (lt) 2017-01-10
CO6862153A2 (es) 2014-02-10
SG10201606883QA (en) 2016-10-28
HUE030300T2 (en) 2017-04-28
AU2012299295A1 (en) 2014-02-20
IL230487B (en) 2019-06-30
EP2744332A4 (en) 2015-01-14
MX354676B (es) 2018-03-15
IN2014CN00572A (es) 2015-04-03

Similar Documents

Publication Publication Date Title
CL2017000293A1 (es) Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)
ECSP14004812A (es) Triazolopiridinas sustituidas
MX373711B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CO6811860A2 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CL2016000381A1 (es) Compuestos antivirales
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
CR20140405A (es) Apoptosis señal reguladores del inhibidor de quinasa
MX2020011810A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CR20150629A (es) Compuestos químicos
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP13013011A (es) Triazolopiridinas
CR20130671A (es) Antagonistas de trpv4
CO6650348A2 (es) Triazolopiridinas sustituidas
CR20130054A (es) Procesos para preparar compuestos antivirales
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
AR095353A1 (es) Compuesto
DOP2016000232A (es) Compuestos químicos
AR102569A1 (es) Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende
AR086606A1 (es) Compuestos del complejo de fe(iii) para el tratamiento y profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro
AR101389A1 (es) Composición que contiene apomorfina y un catión de metal divalente